Core Viewpoint - The company, Awei Technology Co., Ltd., is making a strategic investment of 10 million RMB in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake, which aligns with its long-term development goals and aims to enhance its competitive edge in the medical imaging sector [2][13][14]. Investment Overview - The total investment amount for this round is 30 million RMB, with Awei Technology contributing 10 million RMB to subscribe for 249.3766 thousand RMB of the new registered capital of Luying Technology [4][8]. - The investment does not require board or shareholder approval as it falls within the general manager's authority and has completed internal decision-making processes [5][14]. Target Company Information - Hunan Luying Technology Co., Ltd. specializes in the development of high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [6][13]. - The company was established less than a year ago and currently does not have any sales revenue or profit [6][16]. Market Context - The global medical imaging and radiation therapy equipment market is experiencing rapid and stable growth, with significant government support for the domestic nuclear medicine industry, particularly in promoting the localization of nuclear medicine imaging equipment [13][14]. - SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has a strong market outlook, making it a strategic area for investment [13][14]. Strategic Implications - This investment is expected to deepen synergies within the company's main business and enhance its overall competitiveness, aligning with its strategic development plans [13][14]. - The funding for this investment comes from the company's own resources and will not adversely affect its normal operations or financial status [14]. Future Considerations - The success of this investment will depend on Luying Technology's future operational performance and its ability to navigate various risks associated with market conditions, technology development, and regulatory approvals [16].

Core Viewpoint - Awei Technology plans to invest 10 million yuan in Hunan Luying Technology Co., Ltd., marking its entry into the high-end nuclear medicine imaging equipment sector [1][2]. Investment Details - Awei Technology will invest 10 million yuan, participating in a total capital increase of 30 million yuan alongside other investors [1]. - After the investment, Awei Technology will hold a 9.07% stake in Luying Technology [1]. - The investment decision was made within the general manager's approval authority, requiring no board or shareholder meeting approval [1]. Company Background - Luying Technology, established on April 29, 2025, focuses on the development of domestic high-resolution single-photon emission computed tomography (SPECT) and its core components [1][3]. - The company aims to provide precise, safe, economical, and convenient molecular imaging diagnostic solutions [3]. Market Context - The global medical imaging and radiotherapy equipment market is experiencing rapid and stable growth [2]. - Government policies are promoting the domestic production of nuclear medicine imaging equipment, supporting the industry's development [2]. Product and Technology Insights - SPECT/CT is recognized for its clinical value in early diagnosis and evaluation of tumors, as well as its importance in cardiovascular, bone, and neurological imaging [2]. - Luying Technology's project team has experience in obtaining regulatory approval for SPECT/CT devices and holds core intellectual property, positioning it at an advanced level domestically [3]. Management and Ownership - The controlling shareholders of Luying Technology include key figures from Hunan University, indicating a strong academic and technical foundation [3]. - The company currently has no sales revenue and is still in the product development phase, which presents uncertainties regarding future profitability [3].